Acquisitions - Schedule of Consideration Paid for Merger (Details) - USD ($) $ in Thousands		12 Months Ended
	Oct. 31, 2024	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Asset Acquisition [Line Items]
Common Stock		$ 33,972	$ 36,011	$ 0
Contingent consideration payable		$ 0	$ 11,404	$ 0
ImmPACT Bio USA Inc.
Asset Acquisition [Line Items]
Cash	$ 41,913
Common Stock	36,011
Representative holdback	200
Contingent consideration payable	11,404
Company’s capitalizable transaction expenses	4,215
Total consideration paid	93,743
Cash acquired from acquisition	$ 11,900